JP2015096544A5 - - Google Patents

Download PDF

Info

Publication number
JP2015096544A5
JP2015096544A5 JP2015000566A JP2015000566A JP2015096544A5 JP 2015096544 A5 JP2015096544 A5 JP 2015096544A5 JP 2015000566 A JP2015000566 A JP 2015000566A JP 2015000566 A JP2015000566 A JP 2015000566A JP 2015096544 A5 JP2015096544 A5 JP 2015096544A5
Authority
JP
Japan
Prior art keywords
tumor
group
medicament
compound
ratios
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015000566A
Other languages
English (en)
Japanese (ja)
Other versions
JP5997782B2 (ja
JP2015096544A (ja
Filing date
Publication date
Priority claimed from DE102007047738A external-priority patent/DE102007047738A1/de
Application filed filed Critical
Publication of JP2015096544A publication Critical patent/JP2015096544A/ja
Publication of JP2015096544A5 publication Critical patent/JP2015096544A5/ja
Application granted granted Critical
Publication of JP5997782B2 publication Critical patent/JP5997782B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015000566A 2007-10-05 2015-01-05 イミダゾール誘導体 Expired - Fee Related JP5997782B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007047738.6 2007-10-05
DE102007047738A DE102007047738A1 (de) 2007-10-05 2007-10-05 Imidazolderivate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010527344A Division JP5725860B2 (ja) 2007-10-05 2008-09-09 イミダゾール誘導体

Publications (3)

Publication Number Publication Date
JP2015096544A JP2015096544A (ja) 2015-05-21
JP2015096544A5 true JP2015096544A5 (enExample) 2015-07-30
JP5997782B2 JP5997782B2 (ja) 2016-09-28

Family

ID=40151186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527344A Expired - Fee Related JP5725860B2 (ja) 2007-10-05 2008-09-09 イミダゾール誘導体
JP2015000566A Expired - Fee Related JP5997782B2 (ja) 2007-10-05 2015-01-05 イミダゾール誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010527344A Expired - Fee Related JP5725860B2 (ja) 2007-10-05 2008-09-09 イミダゾール誘導体

Country Status (16)

Country Link
US (1) US20100249132A1 (enExample)
EP (1) EP2193122B1 (enExample)
JP (2) JP5725860B2 (enExample)
KR (1) KR20100075602A (enExample)
CN (1) CN101809001B (enExample)
AR (1) AR068659A1 (enExample)
AU (1) AU2008310117B2 (enExample)
BR (1) BRPI0817609A2 (enExample)
CA (1) CA2701568C (enExample)
DE (1) DE102007047738A1 (enExample)
EA (1) EA201000558A1 (enExample)
ES (1) ES2601139T3 (enExample)
IL (1) IL204683A (enExample)
MX (1) MX2010003368A (enExample)
WO (1) WO2009046804A1 (enExample)
ZA (1) ZA201003125B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009049211A1 (de) * 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
TW201309698A (zh) 2011-03-18 2013-03-01 Ono Pharmaceutical Co 四氫咔啉衍生物
JP6158817B2 (ja) * 2011-10-28 2017-07-05 インヒビタクシン リミテッド 治療に有用なピリダジン誘導体
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
ES2715682T3 (es) 2012-12-19 2019-06-05 Novartis Ag Inhibidores de la autotaxina
MX368059B (es) 2013-07-18 2019-09-18 Novartis Ag Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica.
EP3022201A1 (en) * 2013-07-18 2016-05-25 Novartis AG Autotaxin inhibitors
EP3878848A1 (en) 2013-11-22 2021-09-15 Sabre Therapeutics LLC Autotaxin inhibiting indole compounds
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CN107074822B (zh) * 2014-09-15 2020-01-03 爱杜西亚药品有限公司 作为t型钙通道阻断剂的三唑化合物
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP4026549A1 (en) 2015-05-27 2022-07-13 Sabre Therapeutics LLC Autotaxin inhibitors and uses thereof
HK1252425A1 (zh) 2015-06-05 2019-05-24 Vertex Pharmaceuticals Incorporated 用於治疗脱髓鞘疾病的三唑类药物
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
US20230277490A1 (en) * 2020-07-31 2023-09-07 Cedars-Sinai Medical Center Glutamine as an anticancer therapy in solid tumors
EP4197596A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Imidazole derivatives for the treatment and prophylaxis of infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
DE19954707A1 (de) * 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
ATE420878T1 (de) * 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
FR2889190A1 (fr) * 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant

Similar Documents

Publication Publication Date Title
JP2015096544A5 (enExample)
JP2018510191A5 (enExample)
HRP20120802T1 (hr) Derivati piperidina i piperazina za lijeäśenje tumora
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
HRP20160361T1 (hr) Terapija u kombinaciji s antitumorskim alkaloidom
JP2015523397A5 (enExample)
JP2018109022A5 (enExample)
JP2016528162A5 (enExample)
JP2016528246A5 (enExample)
JP2015512398A5 (enExample)
RU2015104537A (ru) Способы лечения стромальных опухолей желудочно-кишечного тракта
RU2014128513A (ru) Раковый маркер и терапевтическая мишень
JP2017516781A5 (enExample)
JP2016522202A5 (enExample)
TW201613589A (en) Combination methods for treating cancers
MX2018012457A (es) Terapia combinatoria con inhibidores notch y cdk4/6.
MX2019002066A (es) Regimen de dosificacion para el tratamiento de tumores solidos.
JP2015517523A5 (enExample)
JP2016503399A5 (enExample)
JP2009539994A5 (enExample)
JP2019510075A5 (enExample)
JP2008514577A5 (enExample)
JP2021105005A5 (enExample)
JP2009536956A5 (enExample)
MX2020010201A (es) Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado.